GlassScriptPhysician profile
Megan Quella
NPI 1194356535
$1,444.94
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $271 · 2023: $616 · 2024: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255.29 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $202.20 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $201.94 | 2022-2023 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $105.44 | 2022-2023 | Mounjaro, Trulicity |
| Dexcom, INC. | $105.02 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $69.66 | 2023-2024 | Rexulti, Abilify Maintena |
| Insulet Corporation | $68.66 | 2022-2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.48 | 2022-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $46.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.76 | 2023 | |
| Ascendis Pharma Endocrinology INC | $27.98 | 2023 | |
| Lundbeck LLC | $25.21 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $23.43 | 2023 | Auvelity |
| Radius Health, INC. | $23.34 | 2023 | Tymlos |
| Alkermes, INC. | $21.36 | 2024 | Vivitrol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $21.00 | 2023 | Prolastin-C Liquid |
| Recordati_rare_diseases_inc. | $20.75 | 2023 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $20.33 | 2024 | Veozah |
| Medtronic, INC. | $17.51 | 2024 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $16.82 | 2023 | Quviviq |
| Amryt Pharma Holdings LTD | $15.98 | 2023 | Mycapssa |
| Takeda Pharmaceuticals U.S.A., INC. | $15.98 | 2024 | Trintellix |
| Abbvie INC. | $15.32 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.13 | 2023 | Seglentis, Livalo |
| Antares Pharma, INC. | $14.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.23 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Quella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.